Correlations between the ICIQ‐SF score and urodynamic findings

Şeçkiner, İlker; Yeşi̇lli̇, Çeti̇n; Mungan, N.A.; Aykanat, Adem; Akduman, Bülent

doi:10.1002/nau.20389

Cited by 70 publications

(35 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, urinary disturbances based on the Incontinence Questionnaire-Urinary Incontinence Short Form and clinical examination such as urinary frequency, incontinence, and feeling of incomplete emptying were evaluated before and after the treatment [30][31][32]. A positive response was mainly considered as an improvement in motor function, urinary symptoms, and neurologic signs.…”

Section: Clinical Evaluationmentioning

confidence: 99%

Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

et al. 2015

View full text Add to dashboard Cite

Considering that there is no effective treatment for human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis, this study aimed to assess the impact of triple combination therapy-interferon-α, valproic acid, and prednisolone-on clinical outcomes, main HTLV-1 viral factors, and host anti-HTLV-1 antibody response. HTLV-1 proviral load (PVL), and HBZ and Tax mRNA expression levels were measured in peripheral blood mononuclear cells of 13 patients with HTLV-1-associated myelopathy/tropical spastic paraparesis before and after treatment with 180 μg pegylated interferon once a week, 10-20 mg/kg/day sodium valproate, and 5 mg/day prednisolone for 25 weeks using a TaqMan real-time polymerase chain reaction assay. Furthermore, anti-HTLV-1 titer, Osame Motor Disability Score, Ashworth spasticity scale, and urinary symptoms (through standard questionnaire and clinical monitoring) were assessed in patients before and after the treatment. HTLV-1 PVL and HBZ expression significantly decreased after the treatment [PVL from 1443±282 to 660±137 copies/10 4 peripheral blood mononuclear cells (p= 0.01); and HBZ from 8.0±1.5 to 3.0±0.66 (p<0.01)]. Tax mRNA expression decreased after the treatment from 2.26± 0.45 to 1.44±0.64, but this reduction was not statistically significant (p=0.10). Furthermore, anti-HTLV-1 titer reduced dramatically after the treatment, from 3123±395 to 815±239 (p<0.01). Clinical signs and symptoms, according to Osame Motor Disability Score and Ashworth score, improved significantly (both p<0.01). Urinary symptoms and sensory disturbances with lower back pain were reduced, though not to a statistically significant degree. Although signs and symptoms of spasticity were improved, frequent urination and urinary incontinence were not significantly affected by the triple therapy. The results provide new insight into the complicated conditions underlying HTLV-1-associated diseases.

show abstract

Section: Clinical Evaluationmentioning

confidence: 99%

Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The present study showed a significant correlation between this questionnaire and urodynamics, and the questionnaire was considered "gold standard" to assess UI. 30 Hajebrahimi et al reported equivalent results when the questionnaire was answered by the subject or completed by the researcher. 31 When it was not possible to administer questionnaires to a family because of the absence of residents or lack of subjects that could be included in the study, an attempt was made with the next registered family (the family related to the next number).…”

Section: Methodsmentioning

confidence: 98%

Incontinência urinária de esforço em mulheres pertencentes ao Programa de Saúde da Família de Dourados (MS)

Gomes¹,

Silva²

2010

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

StreSS urinary incontinence among women participating in the family health program of DouraDoS (mS), Brazil 649Rev Assoc Med Bras 2010; 56(6): 649-54 IntroductIonUrinary incontinence (UI) is defined as involuntary loss of urine through the urethra. 1 This condition can be classified into three common types: stress urinary incontinence (SUI), urge urinary incontinence (UUI), and mixed urinary incontinence. In SUI, urine leakage occurs when there is increased intraabdominal pressure, such as while practicing physical exercise, coughing, or sneezing. UUI is the inability to hold urine because of a strong need to void. Mixed urinary incontinence is a combination of the two previous conditions. 2 The economic impact of UI is significant both for the public health system and the families of patients with this pathology. In the United States, the cost of the treatment of patients with UI was estimated to be approximately $ 19.5 million in 2000. 3 The annual amount paid for routine care of a U.S. woman with UI was estimated at $ 900.00. 4 Studies have shown the negative impact of UI on the social, sexual, and psychological dimensions. 5 Fultz et al. assessed the impact of UI in 3,364 employed women and demonstrated impairment of work rhythm because of increased frequency of bathroom breaks. 6 Tamanini et al., using the International Consultation on Incontinence Questionnaire (ICIQ-SF), showed that among 225 patients with UI, 8.9% (20) and 17.8% (40) considered the impact of this condition on their quality of life to be severe and very severe, respectively. 7 Telephone interviews conducted in 2003 with 82,196 people over 65 years demonstrated that the prevalence of UI is twice as high in women compared to men and UI is significantly associated with depression. 8 The prevalence of female UI can range from 8.5% to 55%. showed a weak association. Using logistic regression, only pairing of weight and hysterectomy was able to predict the outcome (SUI). Most women with SUI (63.9%) had very severe impairment in the QOL. conclusIon. The prevalence of SUI was similar to that found in other studies; BMI, parity, number of pregnancies, and hysterectomy were associated with this disease, which seriously impairs the QOL.

show abstract

“…Furthermore, standardised and validated questionnaires were prospectively utilized for the evaluation of quality of life (QoL) and satisfaction rate. The following questionnaires were used: "incontinence -QoL" [8] (I-QoL; scale: 0-100, higher score presents better QoL), "Patient Global Impression of Improvement" (PGI-I) [9] (range 1-7, very much better to very much worse), "international consultation on incontinence questionnaire-short form" (ICIQ-SF) [10,11] (range 0-21, 0 = no incontinence, 1-5 = slight, 6-12 = moderate, 13-18 = severe, 19-21 = very severe), "Verbale Rating Scale of Pain" (range 0-10, minimal to maximum pain) for perineum, genitals, inguinal groin and symphysis. The preoperative evaluation included detailed incontinence history, sonography, cystoscopy, and urodynamics if needed.…”

Section: Methodsmentioning

confidence: 99%

The TiLOOP® Male Sling: Did We Forejudge

Hüsch

Kretschmer²,

Thomsen³

et al. 2017

Urol Int

View full text Add to dashboard Cite

Introduction: To evaluate the safety and efficacy of the TiLOOP® male sling (pfm medical, Cologne, Germany) used in the treatment for male stress urinary incontinence (SUI). Material and Methods: We retrospectively evaluated a total of 34 patients with a TiLOOP® male sling. Perioperative complication rates were assessed and validated questionnaires were prospectively evaluated to assess quality of life and satisfaction rate. Outcome and complication rates were analysed by using descriptive statistics. Correlation of continence outcome and risk factors was performed with the chi-square test. A p value below 0.05 was considered statistically significant. Results: The majority of patients (70.6%) were diagnosed with mild or moderate male SUI. During surgery, one instance (2.9%) of intraoperative urethral injury was observed. There were no immediate postoperative complications. The mean follow-up time was 44.6 months. An improvement of male SUI was reported by 61.9% of the patients and 38.1% reported no change according the Patient Global Impression of Improvement. The mean perineal pain score was 0.5 according to the international index of pain. Conclusions: The TiLOOP® is a safe treatment option for male SUI in our cohort with a low complication rate. However, the functional outcome of the TiLOOP® was inferior when compared to the outcome of the AdVance® male sling.

show abstract

Correlations between the ICIQ‐SF score and urodynamic findings

Abstract: ICIQ-SF scoring is a practical and reliable method for baseline and post-treatment evaluation of patients with urge incontinence. Significant correlation exists between ICIQ-SF score and urodynamic parameters.

Cited by 70 publications

References 10 publications

Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Incontinência urinária de esforço em mulheres pertencentes ao Programa de Saúde da Família de Dourados (MS)

The TiLOOP® Male Sling: Did We Forejudge

Contact Info

Product

Resources

About